Cargando…

Chitosan oligosaccharide improves the therapeutic efficacy of sitagliptin for the therapy of Chinese elderly patients with type 2 diabetes mellitus

Sitagliptin improves glycemic control in type 2 diabetes mellitus (T2DM) patients but its side effects are undesirable. Chitosan oligosaccharide (COS) is expected to improve the therapeutic result as a natural product. A total of 200 elderly T2DM patients were evenly assigned into four groups: sitag...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Lijie, Sun, Tingli, Wang, Lina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5499789/ https://www.ncbi.nlm.nih.gov/pubmed/28721055 http://dx.doi.org/10.2147/TCRM.S134039

Ejemplares similares

Predictive Clinical Parameters for the Therapeutic Efficacy of Sitagliptin in Korean Type 2 Diabetes Mellitus
por: Kim, Soon Ae, et al.
Publicado: (2011)

Efficacy and safety of sitagliptin in elderly patients with type 2 diabetes mellitus: A focus on hypoglycemia
por: Fukuda, Masahiro, et al.
Publicado: (2018)

Sitagliptin improves albuminuria in patients with type 2 diabetes mellitus
por: Mori, Hiroko, et al.
Publicado: (2013)

The durability of sitagliptin in elderly patients with type 2 diabetes
por: Hsieh, Ching-Jung, et al.
Publicado: (2014)

Randomized clinical trial of the safety and efficacy of sitagliptin and metformin co‐administered to Chinese patients with type 2 diabetes mellitus
por: Ji, Linong, et al.
Publicado: (2016)

Safety and Efficacy of Sitagliptin-Metformin in Fixed Combination for the Treatment of Type 2 Diabetes Mellitus
por: Ballav, Chitrabhanu, et al.
Publicado: (2013)

Sitagliptin as combination therapy in the treatment of type 2 diabetes mellitus
por: Miller, Shannon A, et al.
Publicado: (2009)

Efficacy of Sitagliptin When Added to Ongoing Therapy in Korean Subjects with Type 2 Diabetes Mellitus
por: Chung, Hye Soo, et al.
Publicado: (2011)

Efficacy and Safety of Taspoglutide Versus Sitagliptin for Type 2 Diabetes Mellitus (T-Emerge 4 Trial)
por: Bergenstal, Richard M., et al.
Publicado: (2012)

Pleiotropic Effects of Sitagliptin in the Treatment of Type 2 Diabetes Mellitus Patients
por: Kubota, Akira, et al.
Publicado: (2012)

Effect of Sitagliptin on Lipid Profile in Patients With Type 2 Diabetes Mellitus
por: Shigematsu, Erina, et al.
Publicado: (2014)

Anti-atherosclerotic effects of sitagliptin in patients with type 2 diabetes mellitus
por: Omoto, Seitaro, et al.
Publicado: (2015)

Effects of Sitagliptin on Insulin and Glucagon Levels in Type 2 Diabetes Mellitus
por: Kim, Ji Hyun
Publicado: (2015)

Cardiovascular risk of sitagliptin in treating patients with type 2 diabetes mellitus
por: Zeng, De-kang, et al.
Publicado: (2019)

Efficacy and safety of titrated canagliflozin in patients with type 2 diabetes mellitus inadequately controlled on metformin and sitagliptin
por: Rodbard, H. W., et al.
Publicado: (2016)

Efficacy and safety of sitagliptin for the treatment of diabetes mellitus complicated by chronic liver injury
por: Asakawa, Masahiro, et al.
Publicado: (2015)

Letter: Predictive Clinical Parameters for the Therapeutic Efficacy of Sitagliptin in Korean Type 2 Diabetes Mellitus (Diabetes Metab J 2011;35:159-65)
por: Oh, Jee-Young
Publicado: (2011)

Response: Predictive Clinical Parameters for the Therapeutic Efficacy of Sitagliptin in Korean Type 2 Diabetes Mellitus (Diabetes Metab J 2011;35:159-65)
por: Kim, Soon Ae, et al.
Publicado: (2011)

Comparison of Serum Ketone Levels and Cardiometabolic Efficacy of Dapagliflozin versus Sitagliptin among Insulin-Treated Chinese Patients with Type 2 Diabetes Mellitus
por: Lee, Chi-Ho, et al.
Publicado: (2022)

Efficacy and Safety of Sitagliptin in Japanese Patients With Type 2 Diabetes
por: Ohmura, Hirotoshi, et al.
Publicado: (2015)

Efficacy and safety of metformin and sitagliptin‐based dual and triple therapy in elderly Chinese patients with type 2 diabetes: Subgroup analysis of STRATEGY study
por: Liu, Xiangyang, et al.
Publicado: (2020)

Optimization of Thiolated Chitosan Nanoparticles for the Enhancement of in Vivo Hypoglycemic Efficacy of Sitagliptin in Streptozotocin-Induced Diabetic Rats
por: Prabahar, Kousalya, et al.
Publicado: (2020)

Hemoglobin level and osteoporosis in Chinese elders with type 2 diabetes mellitus
por: Xiu, Shuangling, et al.
Publicado: (2022)

Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis
por: Engel, Samuel S, et al.
Publicado: (2013)

One year remission of type 1 diabetes mellitus in a patient treated with sitagliptin
por: Lima-Martínez, Marcos M, et al.
Publicado: (2014)

Ten-year follow-up of sitagliptin treatment in patients with type 2 diabetes mellitus
por: Hattori, Sachiko
Publicado: (2021)

Six-Year Complete Remission of Type-1 Diabetes Mellitus in an Adult Treated With Sitagliptin
por: Benido Silva, Vânia, et al.
Publicado: (2023)

Sitagliptin as add-on therapy in insulin deficiency: biomarkers of therapeutic efficacy respond differently in type 1 and type 2 diabetes
por: Giampietro, Ottavio, et al.
Publicado: (2013)

Comparison of the efficacy of sitagliptin and glimepiride dose‐up in Japanese patients with type 2 diabetes poorly controlled by sitagliptin and glimepiride in combination
por: Shimoda, Seiya, et al.
Publicado: (2013)

Effect of sitagliptin on proteinuria in patients with type 2 diabetes – A renoprotective effect of sitagliptin
por: Narimani, Rouhollah, et al.
Publicado: (2021)

Clinical study of repaglinide efficacy and safety in type 2 diabetes mellitus patients with blood glucose levels inadequately controlled by sitagliptin
por: Kawamori, Ryuzo, et al.
Publicado: (2015)

The Glucose-lowering Efficacy of Sitagliptin in Obese Japanese Patients with Type 2 Diabetes
por: Kodera, Ryo, et al.
Publicado: (2017)

Effect of Sitagliptin on Serum Irisin Levels in Patients with Newly Diagnosed Type 2 Diabetes Mellitus
por: Wang, Qiu, et al.
Publicado: (2021)

Factors Predicting Therapeutic Efficacy of Combination Treatment With Sitagliptin and Insulin in Type 2 Diabetic Patients: The ASSIST-K Study
por: Ishikawa, Masashi, et al.
Publicado: (2015)

Papulonodular Lesions in a Patient of Diabetes Mellitus Receiving Sitagliptin and Metformin
por: Agrawal, Prabhat, et al.
Publicado: (2021)

Sitagliptin, sitagliptin and metformin, or sitagliptin and amitriptyline attenuate streptozotocin-nicotinamide induced diabetic neuropathy in rats
por: Sharma, Ashish Kumar, et al.
Publicado: (2012)

Chitin Oligosaccharide and Chitosan Oligosaccharide: Two Similar but Different Plant Elicitors
por: Yin, Heng, et al.
Publicado: (2016)

Secretory units of islets in transplantation index is a useful clinical marker to evaluate the efficacy of sitagliptin in treatment of type 2 diabetes mellitus
por: Kubota, Akira, et al.
Publicado: (2011)

Efficacy and safety of sitagliptin as compared with glimepiride in Japanese patients with type 2 diabetes mellitus aged ≥ 60 years (START‐J trial)
por: Terauchi, Yasuo, et al.
Publicado: (2017)

Factors associated with the glucose‐lowering efficacy of sitagliptin in Japanese patients with type 2 diabetes mellitus: Pooled analysis of Japanese clinical trials
por: Tajima, Naoko, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ngri9h6atr4k87vsl8dcs05l6l